MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-14-2024
T2 Biosystems Market Cap 2011-2026 | TTOO
As of March 17, 2026 T2 Biosystems has a market cap of $ 313 K
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap T2 Biosystems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.78 M | 25 K | 1.33 M | 294 M | 44.6 M | 137 M | 159 M | 143 M | 182 M | 188 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 294 M | 25 K | 116 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
240 M | $ 13.65 | -0.44 % | $ 99.4 M |  Israel |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Bioventus
BVS
|
608 M | $ 8.87 | 2.9 % | $ 591 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 151.97 | -2.34 % | $ 7.53 B | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 25.83 | 1.06 % | $ 717 M | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 17.32 | 1.82 % | $ 923 M | USA |
 |
DexCom
DXCM
|
25.5 B | $ 66.34 | 3.27 % | $ 25.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | $ 103.85 | 0.27 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
467 M | $ 14.95 | 1.22 % | $ 452 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
92.1 M | $ 17.29 | -3.3 % | $ 2.24 B | USA |
 |
Guardant Health
GH
|
13.4 B | $ 87.18 | 1.98 % | $ 10.9 B | USA |
 |
Anixa Biosciences
ANIX
|
104 K | $ 2.84 | 0.35 % | $ 92.2 K | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 191.39 | 2.17 % | $ 136 B | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 97.61 | -0.73 % | $ 8.05 B |  Irlanda |
 |
IQVIA Holdings
IQV
|
28.3 B | $ 164.89 | 0.1 % | $ 28.3 B | USA |
 |
Illumina
ILMN
|
16.4 B | $ 119.28 | 0.29 % | $ 19 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 198.94 | -0.38 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
42 B | $ 111.83 | 0.28 % | $ 34 B | USA |
 |
BioNano Genomics
BNGO
|
3.55 M | $ 1.11 | - | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 8.42 | -6.44 % | $ 239 M | Israel |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 78.5 | -1.25 % | $ 5.3 B | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
34.9 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 453.64 | 0.72 % | $ 13.1 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
28.4 B | $ 1 198.71 | 2.13 % | $ 24.7 B |  Schweiz |
 |
Celcuity
CELC
|
399 M | $ 114.9 | 0.6 % | $ 4.53 B | USA |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 9.11 | 0.22 % | $ 1.98 B | USA |
 |
National Research Corporation
NRC
|
315 M | $ 17.4 | 5.33 % | $ 389 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 8.24 | 4.57 % | $ 1.06 B | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
5.31 B | $ 197.68 | 5.23 % | $ 19.5 B | USA |
 |
OPKO Health
OPK
|
1.21 B | $ 1.19 | - | $ 826 M | USA |
 |
Pacific Biosciences of California
PACB
|
498 M | $ 1.36 | 2.26 % | $ 408 M | USA |